Items where authors include "Bertelli, G."

Export as [feed] Atom [feed] RSS
Jump to: Article
Number of items: 5.

Article

Velikova, G. orcid.org/0000-0003-1899-5942, Morden, J.P., Haviland, J.S. et al. (14 more authors) (2023) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology. ISSN 1470-2045

Adisa, A., Bahrami-Hessari, M., Bhangu, A. orcid.org/0000-0001-5999-4618 et al. (2460 more authors) (2023) Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries. British Journal of Surgery, 110 (7). pp. 804-817. ISSN 0007-1323

Coleman, R.E., Collinson, M., Gregory, W. et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). JOURNAL OF BONE ONCOLOGY, 13. pp. 123-135. ISSN 2212-1374

Brown, J., Rathbone, E., Hinsley, S. et al. (13 more authors) (2018) Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. JNCI: Journal of the National Cancer Institute, 110 (8). pp. 871-879. ISSN 0027-8874

Cameron, D., Morden, J.P., Canney, P. et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045

This list was generated on Sat Mar 23 07:13:36 2024 GMT.